Summary
While in limited animal studies tamoxifen is reported to protect against loss of bone mineral, data in humans are lacking. We measured bone mineral density (BMD) using single photon absorptiometry at the radius and dual photon absorptiometry at the lumbar spine in breast cancer patients treated with chemotherapy at our institution. In this group, 37 women were not treated with tamoxifen (NT) and 48 women were treated with tamoxifen (T) for at least two years. Younger age, greater weight and height, premenopausal status, and shorter time since menopause were found to be significant predictors of greater BMD. Tamoxifen-treated women had been postmenopausal for more years (p = 0.012). Regression analyses used to adjust for differences in risk of bone loss did not reveal significant differences in BMD between the two groups of women. For the postmenopausal women (27 NT and 34 T subjects), the adjusted mean BMD (g/cm2) at the spine was 1.11 (NT), 1.11 (T) (p = 0.93); and at the radius 0.63 (NT), 0.62 (T) (p = 0.30). This limited retrospective study suggests that tamoxifen does not have ‘anti-estrogenic’ effects on BMD.
Article PDF
Avoid common mistakes on your manuscript.
References
Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharm Ther 25: 127–205, 1984
Cummings FJ, Gray R, Davis TE, et al: Adjuvant tamoxifen treatment of elderly women with stage II breast cancer: a double blind comparison with placebo. Ann Int Med 103: 324–329, 1985
Nolvadex Adjuvant Trial: Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Lancet i: 836–840, 1985
Consensus Conference Report: Adjuvant chemotherapy for breast cancer. JAMA 254: 3461–3463, 1985
Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297–302, 1984
Tormey DC: Long-term adjuvant therapy with tamoxifen in breast cancer: How long is long? Ann Int Med 106: 762–764, 1987
Fisher B, Brown A, Wolmark N, et al: Prolonging tamoxifen therapy for primary breast cancer. Ann Int Med 106: 649–654, 1987
Jordan VC: Tamoxifen prophylaxis: prevention is better than cure — prevention is cure?In: Cavalli F (ed) Endocrine Therapy of Breast Cancer: Concepts and Strategies. European School of Oncology Monograph, 1986, pp 117–120
Lindsay R, MacLean A, Kraszewski A, et al: Bone response to termination of oestrogen treatment. Lancet i: 1325–1327, 1978
Christiansen C, Mazess RB, Transbol I, Jensen G: Factors in response to treatment of early postmenopausal bone loss. Calcif Tiss Int 33: 575–581, 1981
Christiansen C: Prevention and treatment of postmenopausal osteoporosis.In: Menczel J, et al (eds) Osteoporosis. Wiley, Chichester, 1982, pp 373–384
Gotfredsen A, et al: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53: 853–857, 1984
Beall PT, Misra LK, Young RL, et al: Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcif Tissue Int 36: 123–125, 1984
Jordan VC, Phelphs E, Lindgren JU: Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31–35, 1987
Mazess RB, Barden HS, Ettinger M, Johnston C, Dawson-Hughes B, Baran P, Powell M, Notelovitz M: Spine and femur density using dual photon absorptiometry in U.S. white women. Bone and Mineral 2: 211–219, 1987
Swenerton KD: Treatment of advanced endometrial carcinoma with tamoxifen. Cancer Treat Rep 64: 805–808, 1980
Author information
Authors and Affiliations
Additional information
Address all inquiries and reprint requests to: Dr. Richard R. Love, K4/6, Clinical Sciences Center, 600 Highland Avenue, Madison, WI 53792, USA
Rights and permissions
About this article
Cite this article
Love, R.R., Mazess, R.B., Tormey, D.C. et al. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Tr 12, 297–302 (1988). https://doi.org/10.1007/BF01811242
Issue Date:
DOI: https://doi.org/10.1007/BF01811242